SAB Biotherapeutics, Inc.
SABSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, SAB Biotherapeutics, Inc. focuses on Biotechnology services and products. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious. With a market capitalization of $266.1M, it sits in micro-cap territory. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Market Cap
$266.1M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.90
EPS (TTM)
$-0.58
EPS (Fwd)
$-0.89
ROE
-0.3%
ROA
-25.4%
Cash
$107.4M
Total Debt
$6.2M
Free CF
-$31.5M
52W Change
86.3%
Annual Financials
Cash vs Debt
With $107.4M in cash and $6.2M in debt, SABS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$31.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -0.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, SABS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SAB Biotherapeutics, Inc. and its sector.